Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation

Inclusion Criteria: * male or female ≥18 years and ≤ 85 years * colonoscopy procedure indicated * willing to stay in the outpatient clinical site for colonoscopy and questionnaire completion * willing and able to undergo study-related procedures * informed consent signed by a patient for participation in the study * negative pregnancy test in women with childbearing potential and consent for double barrier method birth control for subjects, men and women, during the study Exclusion Criteria: * ileus * suspected colonic tumor with manifestations of intestinal obstruction * delayed gastric emptying (gastroparesis), weak vomiting reflex, tendency to aspiration and regurgitation * toxic megacolon which is a result of severe inflammatory conditions of the colon including Crohn's disease and ulcerative colitis * suspected intestinal perforation or risk of gastrointestinal perforation * signs of severe intestinal bleeding * acute inflammatory anal or perianal pathology * severe concomitant diseases of internal organs * psychiatric diseases in aggravation stage * hypersensitivity to polyethylene glycol and/or any component of MOVIPREP® preparation * phenylketonuria or diagnosed glucose-6-phosphate dehydrogenate deficiency * unconsciousness * dehydration * severe inflammatory diseases * acute abdominal pain of unknown etiology * pregnancy and lactation period * participation in any other clinical study (including studies of experimental devices) in 30 days prior participation in the present trial * patients who test positive for human immunodeficiency virus (HIV)/autoimmune disease (AID), Wasserman reaction (RW) or hepatitis B virus (HBC) * any condition or circumstance that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of study data